Figure legends
FIGURE 1 CD19 CAR T cells are highly effective against MPAL patients.
(A) CAR T cell proliferation and persistence. Percentages of CD19 CAR T cells in peripheral blood were measured by flow cytometry before and after infusion. (B) FDG uptake in neck infiltrating loci disappeared after CAR T therapy. (C) Leukemia blasts in bone marrow aspirate before and post infusion were measured by Wright-Giemsa staining. (D) Cytokine levels in peripheral blood of patients were measured by ELISA assay at indicated time points after infusion.